Sorrento Therapeutics, Inc.
SRNE · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.00 | -0.00 |
| FCF Yield | -8,277.34% | -2,120.76% | -1,256.68% | -3,883.42% |
| EV / EBITDA | -0.21 | -0.49 | -0.47 | -0.90 |
| Quality | ||||
| ROIC | -286.80% | -57.00% | -42.95% | -40.16% |
| Gross Margin | 46.77% | 75.37% | 75.14% | 61.07% |
| Cash Conversion Ratio | 0.51 | 0.66 | 0.51 | 0.48 |
| Growth | ||||
| Revenue 3-Year CAGR | 16.26% | 18.95% | 23.57% | -40.85% |
| Free Cash Flow Growth | -5.79% | -47.47% | -6.87% | -38.71% |
| Safety | ||||
| Net Debt / EBITDA | -0.21 | -0.46 | -0.41 | -0.88 |
| Interest Coverage | -58.82 | -36.00 | -9.99 | -5.40 |
| Efficiency | ||||
| Inventory Turnover | 3.35 | 1.61 | 5.43 | 3.64 |
| Cash Conversion Cycle | -267.47 | -411.70 | -698.44 | -555.33 |